145 related articles for article (PubMed ID: 16167287)
1. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
Rouland JF; Le Pen C; Benhaddi H; Piriou E; Lilliu H; Kenigsberg PA;
Eur J Ophthalmol; 2005; 15(5):562-80. PubMed ID: 16167287
[TBL] [Abstract][Full Text] [Related]
2. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years.
Rouland JF; Le Pen C; Benhaddi H; Piriou E; Lilliu H; Kenigsberg PA; The Glaucoma Study Group F
Eur J Ophthalmol; 2005 Sep - Oct 2005; 15(5):562-580. PubMed ID: 28221459
[TBL] [Abstract][Full Text] [Related]
3. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.
Rouland JF; Le Pen C;
Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S5-20. PubMed ID: 12948049
[TBL] [Abstract][Full Text] [Related]
4. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
5. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension.
Day DG; Schacknow PN; Sharpe ED; Ellyn JC; Kulze JC; Threlkeld AB; Jones ED; Brown RH; Jenkins JN; Stewart WC
J Ocul Pharmacol Ther; 2004 Oct; 20(5):383-92. PubMed ID: 15650513
[TBL] [Abstract][Full Text] [Related]
6. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France.
Bernard LM; Althin R; Dhawan R; Grima DT; Lam A; Aballéa S
Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S30-43. PubMed ID: 12948051
[TBL] [Abstract][Full Text] [Related]
9. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
10. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Schachar RA; Raber S; Courtney R; Zhang M
Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
[TBL] [Abstract][Full Text] [Related]
11. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.
Peeters A; Schouten JS; Severens JL; Hendrikse F; Prins MH; Webers CA
Acta Ophthalmol; 2012 Mar; 90(2):146-54. PubMed ID: 20731623
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
14. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
García Sanchez J
Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
[TBL] [Abstract][Full Text] [Related]
16. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies.
Hamacher T; Schinzel M; Schölzel-Klatt A; Neff HM; Maier H; Schlaffer G; Beausencourt E; Jütte M; Scholz R; Lorger C; Stewart WC
Br J Ophthalmol; 2004 Oct; 88(10):1295-8. PubMed ID: 15377554
[TBL] [Abstract][Full Text] [Related]
17. Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy.
Sonty S; Henry JC; Sharpe ED; Weiss MJ; Stewart JA; Nelson LA; Stewart WC
Acta Ophthalmol; 2008 Jun; 86(4):419-23. PubMed ID: 18039347
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
Shin DH; Feldman RM; Sheu WP;
Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
20. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.
Kobelt G; Jönsson L; Gerdtham U; Krieglstein GK
Graefes Arch Clin Exp Ophthalmol; 1998 Nov; 236(11):811-21. PubMed ID: 9825256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
